1. Home
  2. Live Updates
  3. Disease rating scale

Live Breaking News & Updates on Disease rating scale

Stay informed with the latest breaking news from Disease rating scale on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Disease rating scale and stay connected to the pulse of your community

Lixisenatide Decreases Motor Disability Progression in Early Parkinson Disease

Among patients with PD, lixisenatide is associated with a decrease in motor disability progression and has gastrointestinal side effects.

France , Movement-disorder-society , New-england-journal , Unified-parkinson , Disease-rating-scale ,

Subcutaneous Infusion of Levodopa-Carbidopa Beneficial for Parkinson Disease

Researchers found that compared with oral levodopa-carbidopa, treatment with subcutaneous ND0612 provided an additional 1.72 hours of on time without troublesome dyskinesia.

Albertoj-espay , Movement-disorders-society , University-of-cincinnati , Healthday-news , Movement-disorders-society-unified-parkinson , Disease-rating-scale , Patients-global-impression , Clinical-global-impression ,

GlobalData : Roche's PRX-002 shows promise in slowing Parkinson's disease motor progression, says GlobalData

19 Apr, 2024 Roche's PRX-002 shows promise in slowing Parkinson's disease motor progression, says GlobalData



Share


Print...

United-states , American , Lorraine-palmer , Parkinson-progression-marker-initiative , Movement-disorder-society , American-academy-of-neurology , American-academy , Pharma-analyst , Progression-marker-initiative , Movement-disorder-society-sponsored-revision , Unified-parkinson , Disease-rating-scale

Monoclonal antibody Prasinezumab shows promise in slowing rapid Parkinson's progression

A recent study in Nature Medicine evaluated the efficacy of prasinezumab, a monoclonal antibody, in slowing the progression of motor symptoms in Parkinson’s disease patients with rapidly progressing forms, using phase II clinical trial data.

Nature-medicine , Movement-disorder-society-unified-parkinson , Disease-rating-scale , Antibody , Onoclonal-antibody , Alignant , Edicine , Eurons , Henotype , Lacebo ,

Subcutaneous Infusion of Levodopa-Carbidopa Beneficial for Parkinson Disease

Subcutaneous infusion of ND0612 increases on time without troublesome dyskinesia among patients with Parkinson disease.

Albertoj-espay , University-of-cincinnati , Movement-disorders-society , Healthday-news , Movement-disorders-society-unified-parkinson , Disease-rating-scale , Patients-global-impression , Clinical-global-impression ,

Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson's Disease

Cerevel Therapeutics Announces Positive Topline Results for Tavapadon in Phase 3 Adjunctive Trial for People Living with Parkinson's Disease
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Cambridge , Cambridgeshire , United-kingdom , Constance-brown , Raymond-sanchez , Huberth-fernandez , Clinical-development-program , Movement-disorder-society , Neurological-restoration , Disease-rating-scale , Cerevel-therapeutics , Note-regarding-forward-looking

Revealing our Research Project of the Year finalists

Pushing the boundaries within nutritional scientific research, the finalists for the 2024 NutraIngredients award for research project of the year have been announced.

Switzerland , Nikki-hancocks , Chromaddex-external-research-program , Brudy-labs , External-research-program , Movement-disorder-society-unified-parkinson , Disease-rating-scale ,

Phase 2 trial reveals Lixisenatide may reduce motor disability in Parkinson's patients

Phase 2 trial reveals Lixisenatide may reduce motor disability in Parkinson's patients
news-medical.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news-medical.net Daily Mail and Mail on Sunday newspapers.

France , Montreal , Quebec , Canada , Movement-disorder-society , New-england-journal , Early-parkinson , Image-credit , Disease-questionnaire , Unified-parkinson , Disease-rating-scale

Subcutaneous Infusion of Levodopa-Carbidopa Beneficial for Parkinson Disease

Infusion increases on time without troublesome dyskinesia and reduces daily off time

Albertoj-espay , University-of-cincinnati , Movement-disorders-society , Healthday-news , Movement-disorders-society-unified-parkinson , Disease-rating-scale , Patients-global-impression , Clinical-global-impression ,

Sun Pharma Advanced slips 5% on halting Parkinson's drug trial

The Sun Pharma Advanced Research Company stock has gained 40 percent this year against a 4 percent rise in the benchmark Nifty50

United-states , Mumbai , Maharashtra , India , Sun-pharma-advanced-research-company , National-stock-exchange , Movement-disorder-society , Unified-parkinson , Disease-rating-scale , Sun-pharma-advanced-research-company-share-price-today , Un-pharma-advanced-research-company-share-price-update